660862-48-6

Basic information

• Product Name: (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate
• Synonyms: (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate
• CAS NO: 660862-48-6
• Molecular Formula: C16H30N2O5
• Molecular Weight: 330.4198
• EINECS: -0
• Mol File: 660862-48-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate(660862-48-6)
• EPA Substance Registry System: (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate(660862-48-6)

Safety Data

• Hazardous Substances Data: 660862-48-6(Hazardous Substances Data)

Usage

General Description

(S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate is a chemical compound that is commonly used in the pharmaceutical industry as a potential treatment for a variety of conditions, including anxiety, depression, and schizophrenia. It is a derivative of piperazine, a heterocyclic amine with two nitrogen atoms in a six-membered ring, and contains a hydroxyethyl group and two carboxylic acid groups. The di-tert-butyl substituents on the piperazine ring contribute to the compound's stability and lipophilicity, making it a favorable candidate for drug development. Studies have shown that (S)-di-tert-Butyl 2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate exhibits potential therapeutic effects on the central nervous system, making it a promising compound for further research and development.

Upstream product

• 660862-47-5 (S)-2-(piperazin-2-yl)ethan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).